![Douglas Loh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Douglas Loh
Corporate Officer/Principal bei
Australia Institute of Co. Directors
Vermögen: 1 Mio $ am 31.05.2026
Profil
Douglas Loh is currently a Member at the Australia Institute of Co. Directors.
Former roles include Chief Financial Officer at Biome Australia Ltd. from 2021 to 2026, Non-Executive Chairman at DXN Ltd. from 2019 to 2020, Executive Director at Pulse Health Ltd. from 2013 to 2016, Director at Health Science Innovation Holdings Pty Ltd. from 2013 to 2016, and Chief Operating Officer at Acorn Capital Ltd. from 1998 to 2017.
Education includes an undergraduate degree from Monash University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOME AUSTRALIA LTD 3,83 % | 10.06.2026 | 8 739 288 ( 3,83 % ) | 1 Mio $ | 31.05.2026 |
Aktive Positionen von Douglas Loh
| Unternehmen | Position | Beginn |
|---|---|---|
Australia Institute of Co. Directors | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Douglas Loh
| Unternehmen | Position | Ende |
|---|---|---|
| BIOME AUSTRALIA LIMITED | Finanzdirektor/CFO | 02.02.2026 |
| DXN LIMITED | Vorsitzender | 17.03.2020 |
Acorn Capital Ltd.
 Acorn Capital Ltd. Investment ManagersFinance Acorn Capital is a fundamental-oriented manager which seeks to generate long-term outperformance through its distinctive research and investment capabilities and to identify attractive opportunities in less efficient markets. They target the management of small to emerging company portfolios for clients. The firm's investment philosophy is based on its belief that there are pricing inefficiencies amongst Emerging Companies due to a lack of readily available external research conducted on such entities. They believe that through a research driven investment process the inefficiencies that exist in Emerging Companies can be exploited to earn superior returns. | Geschäftsführer | 01.12.2017 |
| PULSE HEALTH LIMITED | Direktor/Vorstandsmitglied | 01.01.2016 |
Health Science Innovation Holdings Pty Ltd. | Direktor/Vorstandsmitglied | 01.01.2016 |
Ausbildung von Douglas Loh
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
73
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Pulse Health Ltd.
 Pulse Health Ltd. Medical/Nursing ServicesHealth Services Acquires and operates private hospitals and related health care services | Health Services |
Acorn Capital Ltd.
Acorn Capital Ltd. Investment ManagersFinance Acorn Capital is a fundamental-oriented manager which seeks to generate long-term outperformance through its distinctive research and investment capabilities and to identify attractive opportunities in less efficient markets. They target the management of small to emerging company portfolios for clients. The firm's investment philosophy is based on its belief that there are pricing inefficiencies amongst Emerging Companies due to a lack of readily available external research conducted on such entities. They believe that through a research driven investment process the inefficiencies that exist in Emerging Companies can be exploited to earn superior returns. | Finance |
Monash University
 Monash University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Australia Institute of Co. Directors | |
DXN Ltd.
 DXN Ltd. Data Processing ServicesTechnology Services Designs, builds, owns and operates data centres | Technology Services |
Health Science Innovation Holdings Pty Ltd. | |
Biome Australia Ltd.
 Biome Australia Ltd. Pharmaceuticals: MajorHealth Technology Develops and markets evidence-based complementary medicines, nutraceuticals & live bio-therapeutics | Health Technology |
